The COVID-19 pandemic has placed an unprecedented strain on drug and vaccine research because of limitations on travel and access to clinical research sites. (For more information, see COVID-19 and Clinical Trials: The Medidata Perspective.)
One way Medidata is supporting the continuation of trials during these times is by aligning its imaging workflow solution to rapidly, securely, and remotely assist researchers in critical document acquisition and source document review.
Medidata Remote Source Review, a quick-to-implement technology built on Medidata's industry-leading Rave Imaging system, is already deployed in more than 15,000 clinical sites.
This 21 CFR Part 11 compliant solution is especially valuable when studies have critical timelines, and there are no secure options to collect, review, de-identify, and redact Personally Identifiable Information.
Less secure, antiquated tools such as fax, email, video, and file sharing software solutions place timelines and data integrity at risk. Remote Source Review also helps improve clinical research associate productivity by decreasing travel time and costs.
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialisation.
Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimise risk, and optimise outcomes.
It is owned by Dassault Systèmes.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma